107 related articles for article (PubMed ID: 27910710)
21. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma.
Sanno N; Teramoto A; Osamura RY
J Neurosurg; 2000 Aug; 93(2):194-200. PubMed ID: 10930003
[TBL] [Abstract][Full Text] [Related]
22. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
23. Thyrotropin secreting pituitary adenoma associated with hypopituitarism and diabetes insipidus in an adolescent boy.
Phillip M; Hershkovitz E; Kornmehl P; Cohen A; Leiberman E
J Pediatr Endocrinol Metab; 1995; 8(1):47-50. PubMed ID: 7584697
[TBL] [Abstract][Full Text] [Related]
24. [Thyreotropic adenoma: review of the literature. Apropos of 2 cases].
Prévost G; Vantyghem MC; Hober C; Evrard A; Huglo D; Bonneville L; Epelbaum J; Lefebvre J
Ann Endocrinol (Paris); 1996; 57(3):194-202. PubMed ID: 8949414
[TBL] [Abstract][Full Text] [Related]
25. Octreotide LAR treatment throughout pregnancy in an acromegalic woman.
Fassnacht M; Capeller B; Arlt W; Steck T; Allolio B
Clin Endocrinol (Oxf); 2001 Sep; 55(3):411-5. PubMed ID: 11589686
[TBL] [Abstract][Full Text] [Related]
26. Octreotide changes serum thyrotropin (TSH) glycoisomer distribution as assessed by lectin chromatography in a TSH macroadenoma patient.
Francis TB; Smallridge RC; Kane J; Magner JA
J Clin Endocrinol Metab; 1993 Jul; 77(1):183-7. PubMed ID: 8325941
[TBL] [Abstract][Full Text] [Related]
27. Successful pregnancy in an acromegalic women treated with octreotide.
Takeuchi K; Funakoshi T; Oomori S; Maruo T
Obstet Gynecol; 1999 May; 93(5 Pt 2):848. PubMed ID: 10912424
[No Abstract] [Full Text] [Related]
28. Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.
Orme SM; Lamb JT; Nelson M; Belchetz PE
Postgrad Med J; 1991 May; 67(787):466-8. PubMed ID: 1852668
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
30. [Response of thyrotropinoma to somatostatin analogues: report of a case].
García Lafuente N; Berná Gascón MT; Pujalte López E; Falcó Jover G; Domínguez Escribano JR
An Med Interna; 2001 Dec; 18(12):663. PubMed ID: 11852512
[No Abstract] [Full Text] [Related]
31. Thyroid-stimulating hormone pituitary adenomas.
Clarke MJ; Erickson D; Castro MR; Atkinson JL
J Neurosurg; 2008 Jul; 109(1):17-22. PubMed ID: 18590428
[TBL] [Abstract][Full Text] [Related]
32. Long term treatment of a thyrotropin-secreting microadenoma with somatostatin analogues.
Prieto-Tenreiro A; Díaz-Guardiola P
Arq Bras Endocrinol Metabol; 2010; 54(5):502-6. PubMed ID: 20694413
[TBL] [Abstract][Full Text] [Related]
33. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
[TBL] [Abstract][Full Text] [Related]
34. Acute liver injury and octreotide.
González-Martín JA; Donnay S; Morillas J; Gómez-Aparicio C; Garcia-Cano J; Pérez-Vigara G; Roldán A
Am J Gastroenterol; 1996 Nov; 91(11):2434-5. PubMed ID: 8931436
[TBL] [Abstract][Full Text] [Related]
35. [Hypophyseal thyrotropin adenomas at Yaounde (Cameroon). Analysis of two case reports: improvement with somatostatin analogue (SMS 201-995)].
Nouedoui C; Moukouri E; Juimo AG; Dongmo L; Zok FD; Tapko JB; Muna WF
Tunis Med; 1999 Mar; 77(3):154-8. PubMed ID: 10392035
[No Abstract] [Full Text] [Related]
36. Successful management of octreotide-insensitive thyrotropin-secreting pituitary adenoma with bromocriptine and surgery: A case report and literature review.
Yang C; Wu H; Wang J; Hu M; Xing X; Bao X; Wang R
Medicine (Baltimore); 2017 Sep; 96(36):e8017. PubMed ID: 28885368
[TBL] [Abstract][Full Text] [Related]
37. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
Losa M; Mortini P; Giovanelli M
Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362
[TBL] [Abstract][Full Text] [Related]
38. [Monosymptomatic hyperthyroidism and TSH-producing adenoma: successful therapy with octreotide].
Mayinger B; Axelos D; Pavel M; Hahn EG; Hensen J
Dtsch Med Wochenschr; 1999 Jan; 124(4):73-8. PubMed ID: 10071603
[TBL] [Abstract][Full Text] [Related]
39. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
Sy RA; Bernstein R; Chynn KY; Kourides IA
J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506
[TBL] [Abstract][Full Text] [Related]
40. Antiproliferative effect of octreotide in somatotroph pituitary adenomas: discussion from a single case report.
Delgrange E; Trouillas J; Gustin T; Gilliard C; Donckier JE
Acta Neurochir (Wien); 2001; 143(7):733-6. PubMed ID: 11534696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
